Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that uses the human angiotensin-converting enzyme 2 (ACE2) receptor as a point of entry. The present review discusses the origin and structure of the virus and its mechanism of cell entry followed by the therapeutic p...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology Vol. 884; p. 173455
Main Authors: Sharifkashani, Sourena, Bafrani, Melika Arab, Khaboushan, Alireza Soltani, Pirzadeh, Marzieh, Kheirandish, Ali, Yavarpour_Bali, Hanie, Hessami, Amirhossein, Saghazadeh, Amene, Rezaei, Nima
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 05.10.2020
Subjects:
ACE2
Angiotensin-Converting Enzyme 2
Betacoronavirus - physiology
Coronavirus Infections - drug therapy
Coronavirus Infections - metabolism
Coronavirus Infections - virology
COVID-19
Drug Discovery - methods
Full Length
Humans
Origin
Pandemics
Peptidyl-Dipeptidase A - metabolism
Pneumonia, Viral - drug therapy
Pneumonia, Viral - metabolism
Pneumonia, Viral - virology
Protein Binding - drug effects
Protein Binding - physiology
Receptors, Virus - metabolism
SARS-CoV-2
SARS-CoV2
Spike Glycoprotein, Coronavirus - metabolism
Therapeutic
Transmission
Virus Internalization - drug effects
COVID-19
Origin
ACE2
SARS-CoV2
Therapeutic
Transmission
ISSN:0014-2999, 1879-0712, 1879-0712
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that uses the human angiotensin-converting enzyme 2 (ACE2) receptor as a point of entry. The present review discusses the origin and structure of the virus and its mechanism of cell entry followed by the therapeutic potentials of strategies directed towards SARS-CoV2-ACE2 binding, the renin-angiotensin system, and the kinin-kallikrein system. SARS-CoV2-ACE2 binding-directed approaches mainly consist of targeting receptor binding domain, ACE2 blockers, soluble ACE2, and host protease inhibitors. In conclusion, blocking or manipulating the SARS-CoV2-ACE2 binding interface perhaps offers the best tactic against the virus that should be treated as a fundamental subject of future research.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0014-2999
1879-0712
1879-0712
DOI:10.1016/j.ejphar.2020.173455